Survival rate of sorafenib in advanced liver cancer

Sorafenib (Sorafenib) inhibits tumor cell proliferation, angiogenesis and metastasis by interfering with multiple key signaling pathways and processes, thereby having a therapeutic effect on cancer types such as renal cell carcinoma and hepatocellular carcinoma. However, the specific mechanism of action and effect still need to be determined based on the patient's condition and the guidance of the doctor.

In one trial, patients with advanced hepatocellular carcinoma who received sorafenib had a median survival of nearly 3 months compared with patients who received placebo. At the time the study was stopped, after the second prespecified interim analysis (conducted when 321 patients had died), median survival was 10.7 months for patients in the sorafenib group compared with 7.9 months in the placebo group. The effect of sorafenib on overall survival remained significant after adjustment for baseline prognostic factors affecting survival, supporting the preliminary analysis. The benefit of sorafenib was also consistent across all prespecified stratification groups, including patients with the worst prognosis, such as those with ECOG performance status 1 or 2 or with macroscopic vascular invasion or extrahepatic spread.

The original drug of sorafenib has been launched in China and has entered the scope of medical insurance. Different regions have different reimbursement ratios, and the price after reimbursement may vary. SpecificationsThe price of 0.2g*60 tablets may be around 1,200 yuan. The original drug of sorafenib has also been launched overseas, and there are also generic drugs of sorafenib produced in other countries. The price of 0.2g*60 tablets produced by a Bangladesh pharmaceutical factory is around RMB 450 (the price may fluctuate due to the exchange rate). The ingredients of the original drug are basically the same as those of the generic drugs. For specific prices and drug details, please consult the medical consultant of Yaode.